Egfr for metastatic breast cancer

Nasdaq: MGNX , a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U. Food and Drug Administration FDA has approved Margenza, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The final Overall Survival OS analysis is expected in the second half of The Margenza U. In addition, Margenza can cause infusion related reactions IRRs.

EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it. EGFR inhibitors can be classified as either: tyrosine kinase inhibitors TKI eg, erlotinib, gefitinib : these bind to the tyrosine kinase domain in the epidermal growth factor receptor and stop the activity of the EGFR monoclonal antibodies eg, cetuximab, necitumumab : these bind to the extracellular component of the EGFR and prevent epidermal growth factor from binding to its own receptor, therefore preventing cell division. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-regulation, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and colon cancer. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. More drug approvals. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

Numerous studies by our lab and others demonstrate that epidermal growth factor receptor EGFR plays critical roles in primary breast cancer BC initiation, growth and dissemination. In the current study we sought to identify the mechanisms responsible for this disparity by investigating the function of EGFR across the continuum of the metastatic cascade. We previously established that overexpression of EGFR is sufficient for formation of in situ primary tumors by otherwise nontransformed murine mammary gland cells.

Metrics details. Breast tissue expression of the ERBB proto-oncogene family has been extensively studied. It was recently shown that expression of epidermal growth factor receptor EGFR; c-erbB-1 and epidermal growth factor receptor HER 2 c-erbB-2 can be detected in the serum of breast cancer patients. The clinical relevance of this has not been fully established. EGFR and HER2 immunoassays were conducted in blood from 57 patients in whom paired serum samples were available from the times of primary and metastatic diagnoses , from 96 primary breast cancer patients and from 49 normal individuals.